与阿诺基斯相关的PLCB4与骨髓瘤的免疫疗法反应有关
Guo Liu1, Yu Fang2, Jiamiao Li3
1Department of Spinal Surgery, Xianning Central Hospital, the First Affiliated Hospital of Hubei University of Science and Technology, Xianning, 437100, Hubei, China.
Discover oncology
|February 22, 2025
概括
脂酶Cβ4 (PLCB4) 是骨髓瘤的关键预后生物标志物,与较差的存活率和影响免疫治疗反应有关. 沉默PLCB4抑制瘤生长和PD-L1表达,突出其治疗潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 生物信息学是一种生物信息学.
背景情况:
- 骨髓瘤是一种主要的骨癌,以其侵略性和高转移潜力而闻名.
- 有效的预后生物标志物和骨髓瘤的治疗点仍然是关键的未满足需求.
研究的目的:
- 为了研究与阿诺基斯相关的基因,特别是脂酶Cββ4 (PLCB4) 的作用,作为骨髓瘤的预后生物标志物.
- 探索PLCB4表达与患者生存,免疫微环境和对治疗的反应的相关性.
主要方法:
- 来自TARGET和GSE21257骨髓瘤队列的转录组数据的生物信息分析.
- 试验室内实验涉及基因沉默,以评估对细胞增殖和PD-L1表达的功能影响.
主要成果:
- 确定了PLCB4作为与骨髓瘤患者的生存率下降相关的重要基因.
- 高PLCB4表达与免疫微环境得分和检查点分子负相关,这表明对免疫疗法的影响.
- 静止PLCB4在体外减少了骨髓瘤细胞增殖和PD-L1表达,药物敏感性分析表明对化疗药物的反应发生了变化.
结论:
- PLCB4在骨髓瘤的进展中起着至关重要的作用,并且可以作为一个有价值的预后生物标志物.
- PLCB4对免疫微环境的影响及其与药物敏感性的关联表明它有可能成为改善骨髓瘤治疗策略的治疗点.
相关概念视频
01:27Tumor Immunotherapy
463
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
463
02:49Cancer Therapies
7.5K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.5K
02:50Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K